• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO GU) 2022

February 17 - 19, 2022

  1. Capivasertib
  2. Ceralasertib
  3. Durvalumab
  4. Durvalumab Tremelimumab
  5. Olaparib
  6. Olaparib Durvalumab
  7. Trastuzumab Deruxtecan

PDF

Updated overall survival (OS) analysis for ProCAID: a randomised, double blind, placebo-controlled phase II trial of capivasertib with docetaxel versus docetaxel alone in metastatic castration resistant prostate cancer (mCRPC)

HTML

Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial)

PDF

BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC)

PDF

A phase III, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin ineligible muscle-invasive bladder cancer (MIBC) (VOLGA)

HTML

SUB-urothelial Durvalumab Injection – 1 (SUBDUE-1) – Results from the first nine urothelial cancer patients using a dose-escalation schedule

HTML

EA8185: Phase 2 Study of Bladder-Sparing Chemoradiation (chemoRT) with Durvalumab in Clinical Stage III, Node Positive Urothelial Carcinoma (INSPIRE), an ECOG-ACRIN/NRG Collaboration

HTML

Immune characterization of urothelial bladder carcinoma integrating transurethral resection of bladder tumor (TURBT) samples and serum:  A feasibility study

HTML

Safety lead-in of phase II SBRT and durvalumab with or without tremelimumab for unresectable and cisplatin-ineligible, locally advanced or metastatic bladder cancer.

PDF

Preferences and perceptions of patients with metastatic castration-resistant prostate cancer for treatments and biomarker testing: an international qualitative study

PDF

Real world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US

PDF

Factors associated with gene mutation testing in United States veterans with metastatic castration-resistant prostate cancer

HTML

ADAM: a multi-center, non-interventional, prospective cohort study for determination of prevalence of homologous recombination repair genes mutations (HRRm) in metastatic castrate resistant prostate cancer (mCRPC). Interim analysis

PDF

PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) vs placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

HTML

Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE).

HTML

ORCHID: A phase II study of olaparib in metastatic renal cell carcinoma patients harboring a BAP1 or other DNA repair gene mutations.

HTML

Trial in progress: Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

HTML

Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial

PDF

Primary analysis from DS8201-A-U105: A phase 1b, 2-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (Nivo) in patients (pts) with HER2-expressing urothelial cancer (UC)

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice